EC Greenlights ViiV Healthcare and J&J’s HIV-1 Combo for Adolescents
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced today that
Read moreViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced today that
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read moreAntiinfectives Intelligence (Aii) offers state-of-the-art Time-Kill Assay services to evaluate the dynamic killing effects of antimicrobial agents. This advanced method
Read moreThe leading global biotechnology company advancing protein-based vaccines, Novavax, announced that the European Commission has granted Marketing Authorisation for the
Read moreIn a landmark approval, the U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s FluMist, the only influenza vaccine that
Read moreNovavax, a global leader in protein-based vaccines, has announced that its updated COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more